Aroa Biosurgery's Symphony Reimbursement Rate Maintained for 2027
ARX: $0.505 -4.72% · MC: $179M
US Medicare and Medicaid authorities have maintained the existing outpatient reimbursement rate for Aroa Biosurgery's Symphony wound-care product for 2027. The same rate will also apply to non-sheet products in physicians' offices, which Aroa says creates an opportunity for other versions of its technology. The company's primary focus remains Myriad in hospital inpatient settings, where reimbursement is unaffected by the outpatient changes.

Comments